Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Genprex, Inc.

Ticker
GNPX
Sector
Industry
Report date
November 14, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes general market and biotech sector articles without specific updates on Genprex's business activities.

Recent developments:
  • Sonnet BioTherapeutics named Raghu Rao as interim CEO following the founder's passing, reflecting leadership changes in the biotech sector [N1].
  • Articles discuss retirement savings, equity market recovery, and stock performance comparisons across various sectors including biotech, but do not provide direct updates on Genprex [N2][N3][N4][N5][N6][N7][N8].
Overview

Genprex, Inc. operates in the biotechnology sector, focusing on pioneering gene therapies for diseases with unmet medical needs, including cancer and diabetes. The company has exclusive worldwide licenses for patented gene therapy technologies involving transcription factors Pdx1 and MafA for diabetes treatment. It formed a subsidiary, Convergen Biotech, Inc., to potentially separate its diabetes program from oncology assets. Genprex has sustained operational losses and currently has no revenue. The company maintains liquidity through cash and equivalents and plans to raise additional capital to support clinical development. Its operations are managed as a single segment under US GAAP accounting standards.

Executive summary

Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for oncology and diabetes. The company holds exclusive licenses for gene therapy technologies from the University of Pittsburgh and has presented preclinical data supporting therapeutic potential in Type 1 diabetes. Genprex has no current revenue and has sustained losses, with net loss of approximately $4.2 million reported for Q3 2026. As of September 30, 2026, the company held $15.3 million in cash and equivalents, with strong liquidity ratios. Genprex recognizes the need for additional capital to fund ongoing clinical trials and operations. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for GNPX

Bull case model:

The company has demonstrated preclinical efficacy in non-human primate models for its gene therapy candidates targeting Type 1 diabetes, with presentations at scientific conferences. The formation of a dedicated subsidiary for the diabetes program may allow focused development and commercialization efforts. Genprex's exclusive licenses and patent portfolio provide a foundation for potential future therapies addressing significant unmet medical needs in diabetes and oncology.

Bear case model:

Genprex has no current revenue and has sustained substantial losses since inception, with ongoing net losses reported. The company depends on raising additional capital to fund clinical trials and operations, with uncertainty regarding successful financing. The clinical-stage nature of its programs entails inherent risks related to regulatory approvals, clinical trial outcomes, and commercialization. The company's liquidity, while currently sufficient into mid-2027, may be strained if expenditures accelerate or funding is delayed.

Moat:

Genprex's moat is primarily based on its exclusive licensing agreements with leading research institutions such as the University of Pittsburgh, granting rights to proprietary gene therapy technologies. The company's intellectual property portfolio includes multiple granted patents and pending applications worldwide, covering therapeutic and technical claims. Its focus on novel gene therapies for diabetes and oncology, supported by preclinical data and collaborations, provides a specialized niche. However, as a clinical-stage company without commercial products, its competitive advantage depends on successful development and protection of its licensed technologies.

Risks overview
Risks summary
The primary risk for Genprex is its dependence on securing additional capital to fund ongoing clinical development and operations amid sustained losses and no current revenue.
Risks details:

• Capital and Liquidity Risk: Genprex requires additional capital to continue clinical development and operations. Failure to secure financing could materially impact its financial condition and ability to operate.
• Clinical and Regulatory Risk: The company’s gene therapy candidates are in early clinical stages, with inherent risks of unsuccessful trials or regulatory setbacks.
• Operational Risk: Sustained losses and no current revenue create ongoing operational challenges and reliance on external funding.
• Intellectual Property Risk: The company’s competitive position depends on maintaining exclusive licenses and protecting its patents, which may be challenged.

FINAL FORECAST FOR GNPX

Final take one line
Genprex is a clinical-stage gene therapy company with detailed SEC disclosures and strong liquidity but faces risks from sustained losses and capital needs.
Final take 12 to 24 month view

Business trends: Continued focus on gene therapy development for diabetes and oncology with preclinical and early clinical data supporting therapeutic potential.
Execution milestones: Advancement of clinical trials, potential separation of diabetes program via subsidiary, and securing additional financing.
Key risks: Dependence on capital raising, clinical and regulatory uncertainties, operational losses, and intellectual property protection challenges.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Genprex, Inc. is focused on developing gene therapies targeting unmet medical needs, including oncology and diabetes programs.
  • The company holds exclusive licenses for gene therapy technologies from the University of Pittsburgh, including patents related to Pdx1 and MafA transcription factors for Type 1 and Type 2 diabetes treatment using adeno-associated virus vectors administered into the pancreatic duct [S1].
  • Genprex formed a wholly owned subsidiary, Convergen Biotech, Inc., in February 2025 to potentially separate its diabetes clinical development program from oncology assets [S1].
  • The company has sustained substantial losses since inception and has no current source of revenue, with net losses continuing as of Q3 2026 [S1, S2].
  • Genprex reported cash and cash equivalents of approximately $15.3 million and current assets of about $16.2 million as of September 30, 2026, with current liabilities around $3.8 million, resulting in a current ratio of 4.26 and a cash ratio of 4.04 [S2].
  • The company recognizes the need for additional capital to fund clinical trials and operations, with cash resources estimated to support operations into Q2 2027, but with uncertainty regarding future financing [S1].
  • Research collaborations have presented preclinical data in non-human primate models demonstrating therapeutic potential of their gene therapy candidates for Type 1 diabetes, including decreased insulin requirements and improved glucose tolerance [S1].
  • Genprex changed its accounting policy in 2024 to expense intellectual property costs rather than capitalize them [S1].
  • The company completed two reverse stock splits in 2024 and 2025, adjusting share counts and prices retroactively [S1].
  • Genprex manages its operations as a single segment focused on gene therapy discovery and development [S1].
  • The company’s consolidated financial statements are prepared under US GAAP and include a wholly owned subsidiary that had not initiated operating activity as of December 31, 2025 [S1].
  • Recent news coverage includes general market and biotech sector articles but no specific recent business developments directly related to Genprex [N1, N2, N3, N4, N5, N6, N7, N8].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-30 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2025-04-01 | www.nasdaq.com | Sonnet BioTherapeutics Names Raghu Rao Interim CEO As Founder Passes | https://www.nasdaq.com/articles/sonnet-biotherapeutics-names-raghu-rao-interim-ceo-founder-passes
  • N2 | 2025-04-01 | www.nasdaq.com | How Far $1 Million in Retirement Savings Plus Social Security Goes in Every State | https://www.nasdaq.com/articles/how-far-1-million-retirement-savings-plus-social-security-goes-every-state
  • N3 | 2025-04-01 | www.nasdaq.com | Equity Markets Recover on Strength in Defensive Stocks and Energy Producers | https://www.nasdaq.com/articles/equity-markets-recover-strength-defensive-stocks-and-energy-producers
  • N4 | 2025-04-01 | www.nasdaq.com | Is Palantir Stock Outforming the Nasdaq? | https://www.nasdaq.com/articles/palantir-stock-outforming-nasdaq
  • N5 | 2025-04-01 | www.nasdaq.com | Eastman Chemical Stock: Is EMN Underperforming the Material Sector? | https://www.nasdaq.com/articles/eastman-chemical-stock-emn-underperforming-material-sector
  • N6 | 2025-04-01 | www.nasdaq.com | How Is Viatris’ Stock Performance Compared to Other Biotech Stocks? | https://www.nasdaq.com/articles/how-viatris-stock-performance-compared-other-biotech-stocks
  • N7 | 2025-04-01 | www.nasdaq.com | Host Hotels & Resorts Stock: Is HST Underperforming the Real Estate Sector? | https://www.nasdaq.com/articles/host-hotels-resorts-stock-hst-underperforming-real-estate-sector
  • N8 | 2025-04-01 | www.nasdaq.com | Is Universal Health Stock Underperforming the Dow? | https://www.nasdaq.com/articles/universal-health-stock-underperforming-dow
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine